Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.3% on Analyst Upgrade

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price shot up 5.3% on Wednesday after Freedom Capmkts upgraded the stock to a strong-buy rating. The company traded as high as $51.07 and last traded at $51.3950. Approximately 121,724 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 362,152 shares. The stock had previously closed at $48.79.

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC started coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Finally, Mizuho set a $45.00 price target on Pulse Biosciences in a research report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Insiders Place Their Bets

In related news, COO Liane Teplitsky purchased 1,036 shares of the stock in a transaction dated Wednesday, August 26th. The stock was bought at an average cost of $48.23 per share, with a total value of $49,966.28. Following the purchase, the chief operating officer directly owned 1,036 shares in the company, valued at $49,966.28. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders bought a total of 4,095 shares of company stock valued at $199,931 over the last quarter. Corporate insiders own 74.00% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its stake in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. bought a new position in Pulse Biosciences in the second quarter valued at approximately $28,000. Tower Research Capital LLC TRC boosted its holdings in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the period. Russell Investments Group Ltd. increased its position in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the second quarter worth $158,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Trading Up 2.8%

The stock’s 50 day moving average is $39.87 and its two-hundred day moving average is $28.84. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -46.13 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. On average, research analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.